Charles Schwab’s Co-Diagnostics CODX Stock Holding History

Charles Schwab’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-369	Closed	-$16.4K	–	3627
2023 Q1	$16.4K	Hold	369	–	–	﹤0.01%	3520
2022 Q4	$27.9K	Hold	369	–	–	﹤0.01%	3464
2022 Q3	$36K	Hold	369	–	–	﹤0.01%	3402
2022 Q2	$63K	Hold	369	–	–	﹤0.01%	3357
2022 Q1	$69K	Sell	369 -1,432	-80%	-$297K	﹤0.01%	3476
2021 Q4	$483K	Hold	1,801	–	–	﹤0.01%	3154
2021 Q3	$526K	Hold	1,801	–	–	﹤0.01%	3131
2021 Q2	$446K	Sell	1,801 -1,909	-51%	-$491K	﹤0.01%	3193
2021 Q1	$1.06M	Buy	3,710 +1,611	+77%	+$643K	﹤0.01%	2835
2020 Q4	$586K	Hold	2,099	–	–	﹤0.01%	2935
2020 Q3	$856K	Sell	2,099 -27	-1%	-$13.9K	﹤0.01%	2714
2020 Q2	$1.24M	Buy	+2,126	New	+$970K	﹤0.01%	2564

Other funds holding CODX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

KOC

Koss-Olinger Consulting Gainesville, Florida $1.19B AUM 15.91% 1-Year Est. Return

Charles Schwab's CODX Position: Q2 2023 in Review

Charles Schwab sold out of Co-Diagnostics (CODX) in Q2 2023, closing a stake of 369 shares — an estimated $16.4K sold.

Charles Schwab first reported a position in CODX in Q2 2020 and held it in 12 quarters. The position peaked at $1.24M in Q2 2020. 43 funds tracked by Wall St. Rank hold CODX as of Q2 2023.

Charles Schwab reported no remaining Co-Diagnostics position as of Q2 2023 after selling out during the quarter.
Charles Schwab sold 369 Co-Diagnostics shares in Q2 2023, an estimated $16.4K.
Charles Schwab first reported a position in Co-Diagnostics in Q2 2020 and held it in 12 quarters.
Charles Schwab's Co-Diagnostics position peaked at $1.24M in Q2 2020.
43 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2023.

Based on Charles Schwab's 13F filing for Q2 2023, filed 10 Aug 2023.